K36 Therapeutics

Cambridge, United States

K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies.

$70.0M raised

Jun 2023

Series B

Biotechnology Therapeutics

Top Investors

Eight Roads Ventures Atlas Venture F-Prime Bristol-Myers Squibb Nextech Invest

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about K36 Therapeutics

How much funding has K36 Therapeutics raised?

K36 Therapeutics has raised $70.0M in total funding. The most recent round was Series B. The last funding was announced in June 2023.

Who are K36 Therapeutics's investors?

K36 Therapeutics's investors include Eight Roads Ventures, Atlas Venture, F-Prime, Bristol-Myers Squibb, Nextech Invest.

Where is K36 Therapeutics headquartered?

K36 Therapeutics is headquartered in Cambridge, United States.

What does K36 Therapeutics do?

K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies.

What stage is K36 Therapeutics at?

K36 Therapeutics is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 28, 2023.

MLA

"K36 Therapeutics — Funding & Investors." VCBacked, June 28, 2023, https://www.vcbacked.co/company/k36-therapeutics. Accessed July 2, 2026.

APA

VCBacked. (2023). K36 Therapeutics — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/k36-therapeutics

Wikipedia (cite web)

{{cite web |title=K36 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/k36-therapeutics |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 28, 2023.

Similar Companies in Biotechnology

View all

Renaissance BioScience

Vancouver$599K

Allterum Therapeutics

Advanced Microbiome Interventions

Amsterdam$300K